PMID- 21207204
OWN - NLM
STAT- MEDLINE
DCOM- 20110726
LR  - 20211020
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
VI  - 11
IP  - 2
DP  - 2011 Apr
TI  - Should the metabolic syndrome patient with prediabetes be offered 
      pharmacotherapy?
PG  - 91-8
LID - 10.1007/s11892-010-0170-y [doi]
AB  - Impaired fasting glucose and impaired glucose tolerance reflect perturbations in 
      glucose metabolism and define a prediabetic state in which risk for type 2 
      diabetes mellitus (T2DM) is increased. There is overlap between prediabetes and 
      the metabolic syndrome, which itself increases the risk for T2DM and 
      cardiovascular disease. The utility of medical interventions to prevent 
      progression to diabetes in prediabetic individuals, many of whom also manifest 
      metabolic syndrome, has been examined in several large clinical trials. Intensive 
      lifestyle intervention consistently results in drastic reductions in the 
      incidence of T2DM and reversal of metabolic syndrome. Additionally, 
      pharmacotherapies-including metformin, acarbose, thiazolidinediones, 
      glucagon-like peptide 1 receptor agonists, and renin-angiotensin inhibitors-also 
      reduce diabetes incidence with variable effects on metabolic syndrome components. 
      Taken together, we recommend that prediabetic patients undergo intensive 
      lifestyle intervention, with the addition of pharmacotherapy based on the 
      presence of specific features of the metabolic syndrome, for diabetes prevention.
FAU - Sullivan, Shannon D
AU  - Sullivan SD
AD  - Department of Endocrinology, Washington Hospital Center, 110 Irving Street, NW, 
      Suite 2A-72, Washington, DC 20010, USA. Shannon.d.sullivan@medstar.net
FAU - Ratner, Robert E
AU  - Ratner RE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/drug therapy/economics/prevention & control
MH  - Disease Progression
MH  - Humans
MH  - Life Style
MH  - Metabolic Syndrome/*complications/*drug therapy/epidemiology
MH  - Prediabetic State/*complications/*drug therapy/epidemiology
EDAT- 2011/01/06 06:00
MHDA- 2011/07/27 06:00
CRDT- 2011/01/06 06:00
PHST- 2011/01/06 06:00 [entrez]
PHST- 2011/01/06 06:00 [pubmed]
PHST- 2011/07/27 06:00 [medline]
AID - 10.1007/s11892-010-0170-y [doi]
PST - ppublish
SO  - Curr Diab Rep. 2011 Apr;11(2):91-8. doi: 10.1007/s11892-010-0170-y.